{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:37:43Z","timestamp":1792201063570,"version":"4.4.0"},"reference-count":91,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1097\/ftd.0b013e31827ada88","type":"journal-article","created":{"date-parts":[[2013,1,12]],"date-time":"2013-01-12T10:45:32Z","timestamp":1357987532000},"page":"30-47","source":"Crossref","is-referenced-by-count":86,"title":["Clobazam Therapeutic Drug Monitoring"],"prefix":"10.1097","volume":"35","author":[{"given":"Jose","family":"de Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210129","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","article-title":"Clobazam.","volume":"4","author":"Ng","year":"2007","journal-title":"Neurotherapeutics"},{"key":"R2-3-20210129","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","article-title":"GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam.","volume":"26","author":"Sankar","year":"2012","journal-title":"CNS Drugs"},{"key":"R3-3-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.pbb.2008.03.015","article-title":"The value of genetic and pharmacological approaches to understanding the complexities of GABA(A) receptor subtype functions: the anxiolytic effects of benzodiazepines.","volume":"90","author":"Reynolds","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"R4-3-20210129","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1586\/ern.12.14","article-title":"Clobazam for patients with Lennox-Gastaut syndrome and epilepsy.","volume":"12","author":"Seif-Eddeine","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":". Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome.","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"key":"R6-3-20210129","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","article-title":". Clobazam in the treatment of Lennox-Gastaut syndrome.","volume":"50","author":"Conry","year":"2009","journal-title":"Epilepsia"},{"key":"R7-3-20210129","first-page":"225","article-title":". Therapeutic drug monitoring of clobazam.","volume":"65","author":"Bentue-Ferrer","year":"2010","journal-title":"Therapie"},{"key":"R8-3-20210129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":". AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"R9-3-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":". Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R10-3-20210129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/JCP.0b013e318058244d","article-title":"The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 and CYP2C19 (guest editorial).","volume":"27","author":"de Leon","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"R11-3-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2008.10.002","article-title":"The future (or lack of future) of personalized prescription in psychiatry.","volume":"59","author":"de Leon","year":"2009","journal-title":"Pharmacol Res"},{"key":"R12-3-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/JCP.0b013e3181a497f1","article-title":"Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity, use of repeated dosing and translation into a message understandable to practicing clinicians.","volume":"29","author":"de Leon","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R13-3-20210129","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.psy.46.3.262","article-title":"The dosing of atypical antipsychotics.","volume":"46","author":"de Leon","year":"2005","journal-title":"Psychosomatics"},{"key":"R15-3-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1440-1681.1975.tb03024.x","article-title":"Dose-dependent kinetics of ethotoin in man.","volume":"2","author":"Sjo Hvidberg","year":"1975","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R18-3-20210129","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/10543406.2010.547264","article-title":". Drug dosage individualization in the presence of clinical or demographic factors that have random effects in a linear model.","volume":"22","author":"Diaz","year":"2012","journal-title":"J Biopharm Stat"},{"key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1875692111201010022","article-title":"The role of statistical random-effects linear models in personalized medicine.","volume":"10","author":"Diaz","year":"2012","journal-title":"Curr Pharmacogenomics Person Med"},{"key":"R20-3-20210129","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","article-title":". Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.","volume":"32","author":"Walzer","year":"2012","journal-title":"Pharmacotherapy"},{"key":"R21-3-20210129","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0773.1990.tb00799.x","article-title":". Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam.","volume":"67","author":"Bun","year":"1990","journal-title":"Pharmacol Toxicol"},{"key":"R22-3-20210129","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2125.1981.tb01281.x","article-title":". Clobazam kinetics in the elderly.","volume":"12","author":"Greenblatt","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0773.1994.tb01371.x","article-title":". Pharmacokinetics of a single oral dose of clobazam in patients with liver disease.","volume":"74","author":"Monjanel-Mouterde","year":"1994","journal-title":"Pharmacol Toxicol"},{"key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/BF00542148","article-title":". Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage.","volume":"26","author":"Ochs","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"key":"R25-3-20210129","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2125.1987.tb03051.x","article-title":". The effect of cimetidine on the single dose pharmacokinetics of oral clobazam and N-desmethylclobazam.","volume":"23","author":"Pullar","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"R26-3-20210129","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1365-2125.1987.tb03247.x","article-title":". Pharmacokinetics of N-desmethylclobazam in healthy volunteers and patients with epilepsy.","volume":"24","author":"Pullar","year":"1987","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 1","key":"R27-3-20210129","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1111\/j.1365-2125.1979.tb04665.x","article-title":". Pharmacokinetics of single and multiple doses of clobazam in humans.","volume":"7","author":"Rupp","year":"1979","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl 2","key":"R28-3-20210129","doi-asserted-by":"crossref","first-page":"143S","DOI":"10.1111\/j.1365-2125.1977.tb05741.x","article-title":". Kinetic interaction of nomifensine with a 1,5-benzodiazepine (clobazam).","volume":"4","author":"Rupp","year":"1977","journal-title":"Br J Clin Pharmacol"},{"key":"R29-3-20210129","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2125.1981.tb01180.x","article-title":"Clobazam plasma concentrations: pharmacokinetic study in healthy volunteers and data in epileptic patients.","volume":"11","author":"Tedeschi","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"R30-3-20210129","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/j.1552-4604.1980.tb01717.x","article-title":". Plasma levels of clobazam after 10-, 20-, and 40-mg tablet doses in healthy subjects.","volume":"20","author":"Vallner","year":"1980","journal-title":"J Clin Pharmacol"},{"key":"R31-3-20210129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-198308010-00005","article-title":". Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation.","volume":"8","author":"Greenblatt","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"R32-3-20210129","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1469-8749.2006.tb01325.x","article-title":"Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy.","volume":"48","author":"Aylett","year":"2005","journal-title":"Dev Med Child Neurol"},{"key":"R33-3-20210129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/WNF.0b013e31815cd960","article-title":". Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center.","volume":"31","author":"Montenegro","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"R34-3-20210129","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3851\/IMP1953","article-title":". A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.","volume":"17","author":"Naccarato","year":"2012","journal-title":"Antivir Ther"},{"key":"R35-3-20210129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0387-7604(03)00074-3","article-title":". Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19.","volume":"26","author":"Parmeggiani","year":"2004","journal-title":"Brain Dev"},{"key":"R36-3-20210129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.legalmed.2010.08.002","article-title":". Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate.","volume":"12","author":"Pok","year":"2010","journal-title":"Leg Med (Tokyo)"},{"key":"R37-3-20210129","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.forsciint.2004.03.029","article-title":". Forensic intoxication with clobazam: HPLCDADMSD analysis.","volume":"143","author":"Proenca","year":"2004","journal-title":"Forensic Sci Int"},{"key":"R38-3-20210129","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00007691-200212000-00009","article-title":". Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam.","volume":"24","author":"Contin","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R39-3-20210129","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0387-7604(12)80025-8","article-title":". Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy.","volume":"13","author":"Bardy","year":"1991","journal-title":"Brain Dev"},{"key":"R40-3-20210129","first-page":"287","article-title":". Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers.","volume":"24","author":"Bun","year":"1986","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"R41-3-20210129","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/00007691-199912000-00004","article-title":". Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.","volume":"21","author":"Contin","year":"1999","journal-title":"Ther Drug Monit"},{"key":"R42-3-20210129","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","article-title":". In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19.","volume":"32","author":"Giraud","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R43-3-20210129","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.braindev.2004.02.010","article-title":". A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.","volume":"26","author":"Kosaki","year":"2004","journal-title":"Brain Dev"},{"key":"R44-3-20210129","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0090-9556(25)08020-1","article-title":". Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man.","volume":"11","author":"Levy","year":"1983","journal-title":"Drug Metab Dispos"},{"key":"R45-3-20210129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00007691-199208000-00002","article-title":". Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy.","volume":"14","author":"Sennoune","year":"1992","journal-title":"Ther Drug Monit"},{"key":"R46-3-20210129","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2217\/14622416.9.5.527","article-title":". Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.","volume":"9","author":"Seo","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R47-3-20210129","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1365-2125.1984.tb02558.x","article-title":"Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients.","volume":"18","author":"Jawad","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"R49-3-20210129","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1177\/106002809402800730","article-title":"Clobazam and N-desmethylclobazam serum concentrations in endstage renal failure and hemodialysis.","volume":"28","author":"Roberts","year":"1994","journal-title":"Ann Pharmacother"},{"key":"R50-3-20210129","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200645010-00002","article-title":"Significance of the minor cytochrome P450 3A isoforms.","volume":"45","author":"Daly","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R51-3-20210129","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/pgs.09.53","article-title":"Pharmacogenomics of CYP3A: considerations for HIV treatment.","volume":"10","author":"Lakhman","year":"2009","journal-title":"Pharmacogenomics"},{"key":"R52-3-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1517\/17425255.2.2.171","article-title":"Clinical implications of CYP3A polymorphisms.","volume":"2","author":"Wojnowski","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R53-3-20210129","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","article-title":"Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.","volume":"30","author":"Spina","year":"2008","journal-title":"Clin Ther"},{"key":"R54-3-20210129","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.spen.2010.10.002","article-title":"Developmental pharmacokinetics.","volume":"17","author":"Anderson","year":"2010","journal-title":"Semin Pediatr Neurol"},{"key":"R55-3-20210129","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2174\/138920011796504527","article-title":"Age-related changes in pharmacokinetics.","volume":"12","author":"Shi","year":"2011","journal-title":"Curr Drug Metab"},{"key":"R56-3-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(08)00001-9","article-title":"Gender differences in pharmacological response.","volume":"83","author":"Anderson","year":"2008","journal-title":"Int Rev Neurobiol"},{"key":"R57-3-20210129","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1067\/mcp.2002.128388","article-title":"Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein.","volume":"72","author":"Cummins","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R58-3-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/17425255.3.4.557","article-title":"Alterations in drug disposition during pregnancy: implications for drug therapy.","volume":"3","author":"Hodge","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R59-3-20210129","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000028398","article-title":"The CYP2C19 enzyme polymorphism.","volume":"61","author":"Wedlund","year":"2000","journal-title":"Pharmacology"},{"key":"R60-3-20210129","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1017\/S1092852900020022","article-title":". DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping.","volume":"14","author":"de Leon","year":"2009","journal-title":"CNS Spectr"},{"key":"R61-3-20210129","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1176\/appi.psy.47.1.75","article-title":"Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.","volume":"47","author":"de Leon","year":"2006","journal-title":"Psychosomatics"},{"key":"R62-3-20210129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cll.2008.05.003","article-title":"Pharmacogenetic testing in psychiatry: a review of features and clinical realities.","volume":"28","author":"de Leon","year":"2008","journal-title":"Clin Lab Med"},{"key":"R63-3-20210129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","article-title":". A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.","volume":"79","author":"Sim","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R64-3-20210129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","article-title":"Metabolic drug interactions with newer antipsychotics: a comparative review.","volume":"100","author":"Spina","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R65-3-20210129","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1517\/17425255.2012.660918","article-title":". Interactions between antiepileptics and second-generation antipsychotics.","volume":"8","author":"de Leon","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R67-3-20210129","first-page":"213","article-title":"Gent JP, et al..","volume":"23","author":"Haigh","year":"1987","journal-title":"N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy Br J Clin Pharmacol"},{"key":"R68-3-20210129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1212\/WNL.41.2_Part_1.313","article-title":"Phenytoin toxicity due to interaction with clobazam.","volume":"41","author":"Zifkin","year":"1991","journal-title":"Neurology"},{"key":"R69-3-20210129","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.2042-7158.1984.tb04917.x","article-title":"Plasma concentrations of clobazam and its N-desmethyl metabolite; protection against pentetrazol-induced convulsions in mice.","volume":"36","author":"Haigh","year":"1984","journal-title":"J Pharm Pharmacol"},{"key":"R70-3-20210129","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1528-1157.1996.tb00643.x","article-title":". Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture.","volume":"37","author":"Nakamura","year":"1996","journal-title":"Epilepsia"},{"key":"R71-3-20210129","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2010.12.037","article-title":"Interactions between modulators of the GABA(A) receptor: stiripentol and benzodiazepines.","volume":"654","author":"Fisher","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"R72-3-20210129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.euroneuro.2011.08.004","article-title":". New insights on the consequences of biotransformation processes on the distribution and pharmacodynamic profiles of some neuropsychotropic drugs.","volume":"22","author":"Voicu","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"R73-3-20210129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/BF02439589","article-title":". Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity.","volume":"93","author":"Arendt","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"R74-3-20210129","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0033-3182(10)70664-2","article-title":"The pharmacokinetics of paliperidone versus risperidone.","volume":"51","author":"de Leon","year":"2010","journal-title":"Psychosomatics"},{"key":"R75-3-20210129","first-page":"355","article-title":"Serum and cerebrospinal fluid concentration of clobazam and N-desmethylclobazam.","volume":"22","author":"Laux","year":"1984","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"suppl 1","key":"R76-3-20210129","doi-asserted-by":"crossref","first-page":"41S","DOI":"10.1111\/j.1365-2125.1979.tb04664.x","article-title":". Kinetics and metabolism of clobazam in animals and man.","volume":"7","author":"Volz","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"R77-3-20210129","first-page":"192","article-title":". Antileptazol activity and kinetics of clobazam and N-desmethyl-clobazam in the guinea-pig.","volume":"253","author":"Ballabio","year":"1981","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"R78-3-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2006-946701","article-title":". The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs.","volume":"39","author":"Hendset","year":"2006","journal-title":"Pharmacopsychiatry"},{"issue":"suppl 8","key":"R80-3-20210129","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1111\/j.1528-1157.2000.tb02950.x","article-title":"Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy.","volume":"41","author":"Glauser","year":"2000","journal-title":"Epilepsia"},{"key":"R81-3-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2125.1991.tb05618.x","article-title":". Pharmacodynamic effects of buspirone and clobazam.","volume":"32","author":"Alford","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"R82-3-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000118609","article-title":". Effects of single oral doses of bromazepam, buspirone and clobazam on performance tasks and memory.","volume":"22","author":"Bourin","year":"1989","journal-title":"Neuropsychobiology"},{"key":"R83-3-20210129","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF00637670","article-title":"Effects of single oral doses of clobazam, diazepam and lorazepam on performance tasks and memory.","volume":"32","author":"Patat","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"R84-3-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF00558501","article-title":". Effects of clobazam and clonazepam on saccadic eye movements and other parameters of psychomotor performance.","volume":"37","author":"van der Meyden","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"R85-3-20210129","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2125.1990.tb03616.x","article-title":". Respiratory and sedative effects of clobazam and clonazepam in volunteers.","volume":"29","author":"Wildin","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"R86-3-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2125.1980.tb01731.x","article-title":"The effects of clobazam and lorazepam on aspects of psychomotor performance and car handling ability.","volume":"10","author":"Hindmarch","year":"1980","journal-title":"Br J Clin Pharmacol"},{"key":"R87-3-20210129","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000118145","article-title":"Information processing and benzodiazepines.","volume":"12","author":"Kleindienst-Vanderbeke","year":"1984","journal-title":"Neuropsychobiology"},{"key":"R89-3-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2165\/00003495-198020030-00001","article-title":". Clobazam: a review of its pharmacological properties and therapeutic use in anxiety.","volume":"20","author":"Brogden","year":"1980","journal-title":"Drugs"},{"key":"R90-3-20210129","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/088307389701200311","article-title":". Interactions of clobazam with conventional antiepileptics in children.","volume":"12","author":"Theis","year":"1997","journal-title":"J Child Neurol"},{"key":"R91-3-20210129","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1515\/CCLM.2004.245","article-title":". Therapeutic drug monitoring of old and newer anti-epileptic drugs.","volume":"42","author":"Neels","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"R92-3-20210129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1017\/S031716710003064X","article-title":". Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations.","volume":"17","author":"Guberman","year":"1990","journal-title":"Can J Neurol Sci"},{"key":"R93-3-20210129","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1365-2125.1983.tb02251.x","article-title":". No effect of food intake on clobazam absorption.","volume":"16","author":"Cenraud","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"R94-3-20210129","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/j.1552-4604.1982.tb05711.x","article-title":". Clobazam kinetics: intrasubject variability and effect of food on adsorption.","volume":"22","author":"Divoll","year":"1982","journal-title":"J Clin Pharmacol"},{"key":"R95-3-20210129","first-page":"673","article-title":"Clobazam as an adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.","volume":"7","author":"Leahy","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"suppl 5","key":"R96-3-20210129","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1111\/j.1528-1157.1994.tb05978.x","article-title":"Clobazam in the treatment of epilepsy: a review of the literature.","volume":"35","author":"Remy","year":"1994","journal-title":"Epilepsia"},{"key":"R97-3-20210129","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1586\/14737175.3.6.829","article-title":"Role of clobazam in the treatment of epilepsies.","volume":"3","author":"Montenegro","year":"2003","journal-title":"Expert Rev Neurother"},{"key":"R98-3-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/14656566.2012.647686","article-title":"Clobazam for treatment of epilepsy.","volume":"13","author":"Giarratano","year":"2012","journal-title":"Expert Opin Pharmacother"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e31827ada88","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T17:01:06Z","timestamp":1745946066000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201302000-00003"}},"subtitle":["A Comprehensive Review of the Literature With Proposals to Improve Future Studies"],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e31827ada88","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}